Myovant Sciences Ltd.
MYOV
MYOV was delisted on the 9th of March, 2023.
105 hedge funds and large institutions have $678M invested in Myovant Sciences Ltd. in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 37
3% less funds holding
Funds holding: 108 → 105 (-3)
8% less capital invested
Capital invested by funds: $737M → $678M (-$59M)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
69% less call options, than puts
Call options by funds: $7.65M | Put options by funds: $24.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$11M |
| 2 |
Janus Henderson Group
London,
|
+$5.67M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.79M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.35M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$43.5M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$5.61M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.32M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$4.39M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$3.99M |
MYOV Hedge Fund Activity: Q3 2021 in Review
105 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Myovant Sciences Ltd. (MYOV) for Q3 2021, worth a combined $678M — down 8% from $737M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of MYOV and 14 opened new positions — a net loss of 2 holders — while 37 trimmed existing stakes and 34 added.
The largest buyer was Bellevue Group, adding an estimated $11M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $43.5M sold.
- 105 institutional investors held Myovant Sciences Ltd. (MYOV) as of Q3 2021, down from 108 in Q2 2021.
- Funds reported $678M of Myovant Sciences Ltd. stock for Q3 2021, down 8% quarter-over-quarter.
- 14 funds opened new Myovant Sciences Ltd. positions in Q3 2021 and 16 closed out, a net change of -2 holders.
- The largest Myovant Sciences Ltd. buyer in Q3 2021 was Bellevue Group, an estimated $11M added.
- The largest Myovant Sciences Ltd. seller in Q3 2021 was PFM Health Sciences, an estimated $43.5M sold.
Based on aggregated 13F filings for Q3 2021.